SpringerLink
Log in

The female menopause— now and in the millennium: New treatment options for a better quality of life

  • Original Article
  • Published:
Comprehensive Therapy

Abstract

Estrogen has traditionally been the only agent effective for the prevention and treatment of postmenopausal osteoporosis. Estrogen's positive effects are often outweighed by negative ones. Newer agents provide safer alternatives that should increase compliance and improve quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007–1015

    Article  CAS  PubMed  Google Scholar 

  2. Matthews KA, Cauley J. Menopause and Mid-Life Health Changes. In: Hazzard WR and Blass JP, eds Principles of Geriatric Medicine and Gerontology, 4th ed. New York, NY: McGraw-Hill; 1994.

    Google Scholar 

  3. Fauci, AS, Braunwald E, eds. Harrison's Principles of Internal Medicine, 13th ed. New York, NY: McGraw-Hill; 1994:2021.

    Google Scholar 

  4. Byyny RL, Speroff, L A Clinical Guide for the Care of Older Women: Primary and Preventive Care, 2nd ed. Baltimore, MD: Williams & Wilkins; 1996:21–67.

    Google Scholar 

  5. 1995 Gallup survey.

  6. National Center for Health Statistics. Monthly Vital Statistics Report. 1996;45:3(Suppl):40–42.

    Google Scholar 

  7. 1997 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1996:26,28.

  8. Cancer Facts & Figures-1996. Atlanta, GA: American Cancer Society; 1996:5.

  9. Cancer Facts & Figures-1997. Atlanta, GA: American Cancer Society; 1997:8,13.

  10. National Osteoporosis Foundation. Stand up to osteoporosis: Your guide to staying healthy and independent through prevention and treatment. Washington, DC: 1997:10.

  11. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24–35.

    Article  CAS  PubMed  Google Scholar 

  12. Riggs BL, Melton LJ III. Involutional Osteoporosis. N Engl J Med. 1986;314:1676–1686.

    Article  CAS  PubMed  Google Scholar 

  13. Pacala JT. Osteoporosis and Osteomalacia. In: Geriatric Review Syllabus, 4th ed, Book 1. Cobbs EL, Duthie EH, and Murphy JB, eds. Dubuque, IA: Rendall/Hunt; 1999:138–142.

    Google Scholar 

  14. Kenny AM. Hormone Replacement Therapy. In: Geriatric Review Syllabus, 4th ed, Book. 1. Cobbs EL, Duthie EH, and Murphy JG, eds Dubuque, IA: Kendall/Hunt: 1999:261–264.

    Google Scholar 

  15. Rosano GMC, Sarrel PM, Poole-Wilson PA, Colins P. Beneficial effect of oestrogen on exercise-induced myocardial ischaemia in women with coronary artery disease. Lancet. 1993;342:133–136.

    Article  CAS  PubMed  Google Scholar 

  16. Psaty BM, Heckbert SR, Atkins, D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154:1333–1339.

    Article  CAS  PubMed  Google Scholar 

  17. Manolio TA, Furberg CD, Shemanski L, et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation. 1993;88:2163–2171.

    CAS  PubMed  Google Scholar 

  18. Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease. Ten year follow-up from the Nurses' Health Study. N Engl J Med. 1991;325:756–762.

    Article  CAS  PubMed  Google Scholar 

  19. Goldman L, Tosteson ANA. Uncertainty about postmenopausal estrogen. Time for action, not debate [Editorial]. N Engl J Med. 1991;325:800–802.

    Article  CAS  PubMed  Google Scholar 

  20. Cefalu CA, Marziano ML. The pros and cons of hormone replacement therapy in the female: A practical guide for evaluating clinical needs. In: Vellas B, Albarede JL and Garry PJ, eds. Women, Aging and Health. Paris: Serdi; 1998:157–166.

    Google Scholar 

  21. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle, G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet. 1991;338:274–277.

    Article  CAS  PubMed  Google Scholar 

  22. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women [Letter]. Ann Intern Med. 1992;117:1038–41.

    Google Scholar 

  23. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485–491.

    Article  CAS  PubMed  Google Scholar 

  24. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613.

    Article  CAS  PubMed  Google Scholar 

  25. Chesnut CH, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. Am J Med 2000;109:267–276.

    Article  CAS  PubMed  Google Scholar 

  26. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl J. Med. 1990;323:73–79.

    Article  CAS  PubMed  Google Scholar 

  27. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535–1541.

    Article  CAS  PubMed  Google Scholar 

  28. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077–2082.

    Article  CAS  PubMed  Google Scholar 

  29. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292–299.

    Article  CAS  PubMed  Google Scholar 

  30. Physician's Desk Reference. Montvale, NJ: Medical Economics Company; 1999:1798–1799, 3426.

  31. Lanza FL, Hunt RH, Thompson ABR, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2001;119:631–638.

    Article  Google Scholar 

  32. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344–1352.

    Article  CAS  PubMed  Google Scholar 

  33. Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res. 2000;15:1006–1013.

    Article  CAS  PubMed  Google Scholar 

  34. Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309–2318.

    Article  CAS  PubMed  Google Scholar 

  35. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis porosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637–645.

    Article  CAS  PubMed  Google Scholar 

  36. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999;281:2189–2197.

    Article  CAS  PubMed  Google Scholar 

  37. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451.

    Article  CAS  PubMed  Google Scholar 

  38. Allolio B. Risk factors for hip fracture not related to bone mass and their therapeutic implications. Osteoporos Int. 1999;9[Suppl 2]:S9-S16.

    Article  PubMed  Google Scholar 

  39. Walsh BW, Paul S, Wild RA, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000;85:214–218.

    Article  CAS  PubMed  Google Scholar 

  40. Lindsay R, Cosman F, Lobo, RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076–3081.

    Article  CAS  PubMed  Google Scholar 

  41. Cummings SR, Palermo L, Browner W, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean, Fracture Intervention Trial Research Group. JAMA. 2000;283:1318–1321.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Louisiana State University Medical Center, New Orlean, La

    Cathi Fontenot MD (Clinical Associate Professor of Medicine Chief of Comprehensive Medicine)

  2. Department of Family Medicine, Lousiana State University Medical Center, 1542 Tulane Avenue, 70112-2822, New Orleans, LA, USA

    Charles A. Cefalu MD, MS (Professor and Associate Chairman for Geriatric Program Development)

Authors
  1. Charles A. Cefalu MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cathi Fontenot MD
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Cefalu, C.A., Fontenot, C. The female menopause— now and in the millennium: New treatment options for a better quality of life. Compr Ther 27, 95–103 (2001). https://doi.org/10.1007/s12019-996-0002-9

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12019-996-0002-9

Keywords

Search

Navigation